华润三九医药股份有限公司关于部分限制性股票回购注销完成的公告

Core Viewpoint - The announcement details the completion of the repurchase and cancellation of restricted stocks by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., involving a total of 5,333,927 shares, which accounts for 0.319% of the company's total share capital before the repurchase, with a total repurchase fund amounting to 34,551,411.32 yuan [2][20]. Summary by Sections Repurchase and Cancellation Details - The company has completed the repurchase and cancellation of a total of 5,333,927 restricted stocks, which represents 0.319% of the total share capital prior to the repurchase [2]. - The total amount of funds used for the repurchase is 34,551,411.32 yuan, involving a total of 376 individuals [2][20]. - Following the cancellation, the company's total share capital decreased from 1,669,588,290 shares to 1,664,254,363 shares [3]. Reasons for Repurchase - The repurchase was necessitated by the termination of labor contracts with 5 original incentive recipients, retirement of 8 recipients, and 4 recipients failing to meet performance targets [4][17]. - A total of 585,985 shares were repurchased due to the termination of contracts, accounting for approximately 0.04% of the total share capital before the repurchase [17]. - Additionally, 4,747,942 shares were repurchased due to unmet conditions for the third unlocking period of the incentive plan, representing about 0.28% of the total share capital [17]. Repurchase Price and Funding - The repurchase price for the shares varied, with specific prices set for different groups of recipients based on their circumstances [18][19]. - The total repurchase funds were sourced from the company's own funds [22]. Completion and Impact - The repurchase and cancellation were confirmed by the China Securities Depository and Clearing Corporation on September 9, 2025, and the company has completed the necessary registration changes [22]. - The cancellation of the restricted stocks is in compliance with relevant laws and regulations and will not significantly impact the company's financial status or operational results [22].